This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Cleveland BioLabs's Median PS Value or its related term are showing as below:
CBLI'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 3.56 Med: 14.95 Max: 54.38
Current: 54.38
During the past 13 years, the highest Price to Median PS Value of Cleveland BioLabs was 54.38. The lowest was 3.56. And the median was 14.95.
CBLI's Price-to-Median-PS-Value is not ranked
in the Biotechnology industry.
Industry Median: 0.68
vs CBLI: 54.38
Cleveland BioLabs Median PS Value Historical Data
The historical data trend for Cleveland BioLabs's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cleveland BioLabs's Median PS Value
For the Biotechnology subindustry, Cleveland BioLabs's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cleveland BioLabs's Price-to-Median-PS-Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cleveland BioLabs's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Cleveland BioLabs's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 10.
Cleveland BioLabs's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.008.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cleveland BioLabs (NAS:CBLI) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Cleveland BioLabs's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
4.35
/
0.08
=
54.38
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cleveland BioLabs Median PS Value Related Terms
Thank you for viewing the detailed overview of Cleveland BioLabs's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Cleveland BioLabs (Cleveland BioLabs) Business Description
Cleveland BioLabs Inc is a biopharmaceutical company. The company is developing novel approaches to activate the immune system and address serious medical needs. Its proprietary platform of Toll-like immune receptor activators has applications in the mitigation of radiation injury and immuno-oncology. Its lead product candidate is entolimod, an immuno-stimulatory agent, which is developed as a radiation countermeasure and immunotherapy for oncology and other indications. Entolimod is a Toll-like receptor 5 (TLR5) agonist, which is developed as a radiation countermeasure for the prevention of death from Acute Radiation Syndrome (ARS), and as an oncology drug.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CBLI has been successfully added to your 